The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort
- PMID: 27657686
- PMCID: PMC5440569
- DOI: 10.1038/gim.2016.143
The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort
Abstract
Purpose: It has been argued that rare diseases should be recognized as a public health priority. However, there is a shortage of epidemiological data describing the true burden of rare diseases. This study investigated hospital service use to provide a better understanding of the collective health and economic impacts of rare diseases.
Methods: Novel methodology was developed using a carefully constructed set of diagnostic codes, a selection of rare disease cohorts from hospital administrative data, and advanced data-linkage technologies. Outcomes included health-service use and hospital admission costs.
Results: In 2010, cohort members who were alive represented approximately 2.0% of the Western Australian population. The cohort accounted for 4.6% of people discharged from hospital and 9.9% of hospital discharges, and it had a greater average length of stay than the general population. The total cost of hospital discharges for the cohort represented 10.5% of 2010 state inpatient hospital costs.
Conclusions: This population-based cohort study provides strong new evidence of a marked disparity between the proportion of the population with rare diseases and their combined health-system costs. The methodology will inform future rare-disease studies, and the evidence will guide government strategies for managing the service needs of people living with rare diseases.Genet Med advance online publication 22 September 2016.
Figures
Comment in
-
The need for a next-generation public health response to rare diseases.Genet Med. 2016 Oct 27;19(5):489-490. doi: 10.1038/gim.2016.166. Epub 2016 Oct 27. Genet Med. 2016. PMID: 27787501 Free PMC article. No abstract available.
Similar articles
-
Hospital utilization, costs and mortality rates during the first 5 years of life: a population study of ART and non-ART singletons.Hum Reprod. 2014 Mar;29(3):601-10. doi: 10.1093/humrep/det397. Epub 2013 Dec 4. Hum Reprod. 2014. PMID: 24310618
-
Measuring the impact of rare diseases in Tasmania, Australia.Orphanet J Rare Dis. 2024 Oct 28;19(1):399. doi: 10.1186/s13023-024-03343-2. Orphanet J Rare Dis. 2024. PMID: 39468681 Free PMC article.
-
Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.J Manag Care Pharm. 2008 Mar;14(2):176-85. doi: 10.18553/jmcp.2008.14.2.176. J Manag Care Pharm. 2008. PMID: 18331119 Free PMC article.
-
Healthcare burden of rare diseases in Hong Kong - adopting ORPHAcodes in ICD-10 based healthcare administrative datasets.Orphanet J Rare Dis. 2018 Aug 28;13(1):147. doi: 10.1186/s13023-018-0892-5. Orphanet J Rare Dis. 2018. PMID: 30153866 Free PMC article. Review.
-
Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.Adv Exp Med Biol. 2017;1031:55-94. doi: 10.1007/978-3-319-67144-4_4. Adv Exp Med Biol. 2017. PMID: 29214566 Review.
Cited by
-
Frequency-based rare diagnoses as a novel and accessible approach for studying rare diseases in large datasets: a cross-sectional study.BMC Med Res Methodol. 2023 Jun 17;23(1):143. doi: 10.1186/s12874-023-01972-y. BMC Med Res Methodol. 2023. PMID: 37330464 Free PMC article.
-
Hospital mortality in patients with rare diseases during pandemics: lessons learnt from the COVID-19 and SARS pandemics.Orphanet J Rare Dis. 2021 Aug 12;16(1):361. doi: 10.1186/s13023-021-01994-z. Orphanet J Rare Dis. 2021. PMID: 34384469 Free PMC article.
-
Impact of single and combined rare diseases on adult inpatient outcomes: a retrospective, cross-sectional study of a large inpatient population.Orphanet J Rare Dis. 2021 Feb 27;16(1):105. doi: 10.1186/s13023-021-01737-0. Orphanet J Rare Dis. 2021. PMID: 33639989 Free PMC article.
-
Evaluation of orphan diseases global burden.Eur J Transl Myol. 2021 May 14;31(2):9610. doi: 10.4081/ejtm.2021.9610. Eur J Transl Myol. 2021. PMID: 33985324 Free PMC article.
-
The Epidemiology of Transition into Adulthood of Rare Diseases Patients: Results from a Population-Based Registry.Int J Environ Res Public Health. 2018 Oct 10;15(10):2212. doi: 10.3390/ijerph15102212. Int J Environ Res Public Health. 2018. PMID: 30309015 Free PMC article.
References
-
- Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008;371:2039–2041. - PubMed
-
- European Organisation for Rare Diseases. Rare Diseases: Understanding This Public Health Priority. Eurordis: Paris, France, 2005. http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf. Accessed 7 October 2015.
-
- Groft SC, Posada de la Paz M. Rare diseases—avoiding misconceptions and establishing realities: the need for reliable epidemiological data. In: Groft SC, Posada de la Paz M (eds). Rare Diseases Epidemiology Springer: Dordrecht, The Netherlands, 2010:3–14. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical